How have VRPX shares performed in 2024?

Virpax Pharmaceuticals' stock was trading at $3.2010 at the start of the year. Since then, VRPX stock has increased by 22.1% and is now trading at $3.91. View the best growth stocks for 2024 here .

Are investors shorting Virpax Pharmaceuticals?

Virpax Pharmaceuticals saw a increase in short interest in March. As of March 31st, there was short interest totaling 29,800 shares, an increase of 24.7% from the March 15th total of 23,900 shares. Based on an average trading volume of 23,500 shares, the days-to-cover ratio is presently 1.3 days. Approximately 3.4% of the company's stock are short sold. View Virpax Pharmaceuticals' Short Interest .

When is Virpax Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, May 10th 2024. View our VRPX earnings forecast .

When did Virpax Pharmaceuticals' stock split?

Virpax Pharmaceuticals shares reverse split before market open on Friday, March 1st 2024. The 1-10 reverse split was announced on Friday, March 1st 2024. The number of shares owned by shareholders was adjusted after the closing bell on Friday, March 1st 2024. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

When did Virpax Pharmaceuticals IPO?

Virpax Pharmaceuticals (VRPX) raised $15 million in an initial public offering (IPO) on Wednesday, February 17th 2021. The company issued 1,400,000 shares at a price of $10.00-$12.00 per share. ThinkEquity (a division of Fordham Financial Management) served as the underwriter for the IPO.

How do I buy shares of Virpax Pharmaceuticals?

Shares of VRPX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:VRPX

Virpax Pharmaceuticals (VRPX) Stock Price, News & Analysis

→ Biden replacement revealed? (From Paradigm Press) (Ad)

Free VRPX Stock Alerts

$3.91

+0.44 (+12.68%)

(As of 04/18/2024 ET)

Compare

Today's Range: $3.31
▼
$3.91
50-Day Range: $2.70
▼
$4.95
52-Week Range: $2.40
▼
$11.77

Volume: 20,060 shs
Average Volume: 21,125 shs
Market Capitalization: $4.57 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Get Virpax Pharmaceuticals alerts:

Ad Paradigm Press

Biden replacement revealed?

A former CIA insider just announced a disturbing prediction… Biden will withdraw as the Democrat nominee on June 13.

See his shocking evidence in this new report

About Virpax Pharmaceuticals Stock (NASDAQ:VRPX)

Virpax Pharmaceuticals, Inc., a preclinical-stage pharmaceutical company, develops various drug-delivery systems and drug-releasing technologies focused on advancing non-opioid and non-addictive pain management treatments and treatments for central nervous system disorders. Its preclinical stage product candidates include Epoladerm, a topical spray film delivery technology for osteoarthritis pain; Probudur, an injectable local anesthetic liposomal gel technology for postoperative pain management; and Envelta, a nanotechnology-based intranasal spray drug product candidate that enables the delivery of a metabolically labile peptide drug into the brain. The company's preclinical stage product candidates also comprise PES200, which enables the delivery of a metabolically labile peptide drug into the brain; AnQlar, an anti-viral barrier to prevent or reduce the risk or the intensity of viral infections in humans, including influenza and SARS-CoV-2; and NobrXiol, an investigational formulation to be delivered via the nasal route to enhance cannabidiol transport to the brain. Virpax Pharmaceuticals, Inc. was founded in 2016 and is headquartered in Berwyn, Pennsylvania.

VRPX Stock Price History

30 days | 90 days | 365 days | Advanced Chart

VRPX Stock News Headlines

April 13, 2024 | americanbankingnews.com

Virpax Pharmaceuticals, Inc. (NASDAQ:VRPX) Short Interest Up 24.7% in March

April 2, 2024 | msn.com

Virpax Pharmaceuticals Set for Transformative Year with High Hopes for Non-Addictive Pain Management Solutions

April 19, 2024 | Paradigm Press (Ad)

Biden replacement revealed?

A former CIA insider just announced a disturbing prediction… Biden will withdraw as the Democrat nominee on June 13.

March 26, 2024 | businesswire.com

Virpax Pharmaceuticals Reports 2023 Year-End Results

February 27, 2024 | finance.yahoo.com

Virpax Pharmaceuticals Announces Reverse Stock Split to Regain Compliance with Nasdaq’s Minimum Bid Price

February 27, 2024 | businesswire.com

Virpax Pharmaceuticals Announces Reverse Stock Split to Regain Compliance with Nasdaq's Minimum Bid Price

February 27, 2024 | businesswire.com

Virpax Pharmaceuticals Announces Proposed Settlement of Litigation with Sorrento Therapeutics, Inc. and Scilex Pharmaceuticals, Inc.

February 12, 2024 | msn.com

Virpax Pharmaceuticals Reports Promising Results in Probudur Pilot Study

April 19, 2024 | Paradigm Press (Ad)

Biden replacement revealed?

A former CIA insider just announced a disturbing prediction… Biden will withdraw as the Democrat nominee on June 13.

February 9, 2024 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Virpax Pharmaceuticals (VRPX) and I-MAB (IMAB)

February 7, 2024 | markets.businessinsider.com

Analysts Have Conflicting Sentiments on These Healthcare Companies: Vertex Pharmaceuticals (VRTX) and EyePoint Pharmaceuticals (EYPT)

January 23, 2024 | investing.com

Virpax Pharmaceuticals Inc (VRPX)

December 29, 2023 | msn.com

Virpax Pharmaceuticals shareholders okay reverse stock split

December 28, 2023 | msn.com

Titan Pharmaceuticals to conduct 1-for-20 reverse stock split

November 22, 2023 | seekingalpha.com

VRPX Virpax Pharmaceuticals, Inc.

November 18, 2023 | markets.businessinsider.com

Promising Pipeline Developments and Market Opportunities Drive Buy Rating for Virpax Pharmaceuticals

November 17, 2023 | msn.com

Virpax Pharmaceuticals gets non-compliance notice from Nasdaq

November 17, 2023 | msn.com

Virpax Pharmaceuticals CEO and Chairman resigns on ongoing litigation

November 17, 2023 | finance.yahoo.com

Virpax Pharmaceuticals Announces Leadership Transition

November 17, 2023 | finance.yahoo.com

Virpax Pharmaceuticals Announces Notification from Nasdaq Related to Delayed Form 10-Q Filing

November 15, 2023 | msn.com

Virpax Pharmaceuticals GAAP EPS of -$0.51

October 31, 2023 | finance.yahoo.com

Virpax Pharmaceuticals Announces that Envelta™ Remains on Track for Trial in Humans Following FDA Review

September 28, 2023 | markets.businessinsider.com

Analysts Are Bullish on These Healthcare Stocks: Virpax Pharmaceuticals (VRPX), Kura Oncology (KURA)

September 27, 2023 | finance.yahoo.com

Virpax Pharmaceuticals Announces Results of Probudur™ Dose Escalation Studies

September 26, 2023 | finance.yahoo.com

Virpax Pharmaceuticals to Present at the LD Micro Main Event XVI

September 21, 2023 | businesswire.com

Altasciences Chosen by Virpax to Support the Development of a New Drug to Prevent Spread of Flu-like Viruses

September 18, 2023 | finance.yahoo.com

Virpax Pharmaceuticals Announces the Formation of Novvae™ Pharmaceuticals

See More Headlines

Receive VRPX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Virpax Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today: 4/18/2024
Next Earnings (Estimated): 5/10/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:VRPX
CUSIP: N/A
CIK: 1708331
Web: www.virpaxpharma.com
Phone: 610-727-4597
Fax: N/A
Employees: 7
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): ($11.70)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-15,190,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -169.04%
Return on Assets: -106.39%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 1.25
Quick Ratio: 1.25

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $1.65 per share
Price / Book: 2.45

Miscellaneous

Outstanding Shares: 1,170,000
Free Float: 1,098,000
Market Cap: $4.73 million
Optionable: Not Optionable
Beta: 1.38

The Best High-Yield Dividend Stocks for 2024

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

Key Executives

Mr. Gerald W. Bruce (Age 67)
CEO & Director
Dr. Jeffrey A. Gudin M.D. (Age 58)
Executive VP, Chief Medical Officer & Director
Comp: $204k
Mr. Vinay Shah A.C.A. (Age 62)
M.B.A., CFO, Principal Financial Officer & Principal Accounting Officer
Dr. Sheila A. Mathias J.D.
M.B.A., Ph.D., Chief Scientific Officer
Shana Panzarella
Chief of Staff

Key Competitors

View All Competitors

VRPX Stock Analysis - Frequently Asked Questions

How have VRPX shares performed in 2024?: Virpax Pharmaceuticals' stock was trading at $3.2010 at the start of the year. Since then, VRPX stock has increased by 22.1% and is now trading at $3.91.
View the best growth stocks for 2024 here.
Are investors shorting Virpax Pharmaceuticals?: Virpax Pharmaceuticals saw a increase in short interest in March. As of March 31st, there was short interest totaling 29,800 shares, an increase of 24.7% from the March 15th total of 23,900 shares. Based on an average trading volume of 23,500 shares, the days-to-cover ratio is presently 1.3 days. Approximately 3.4% of the company's stock are short sold.
View Virpax Pharmaceuticals' Short Interest.
When is Virpax Pharmaceuticals' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Friday, May 10th 2024.
View our VRPX earnings forecast.
When did Virpax Pharmaceuticals' stock split?: Virpax Pharmaceuticals shares reverse split before market open on Friday, March 1st 2024. The 1-10 reverse split was announced on Friday, March 1st 2024. The number of shares owned by shareholders was adjusted after the closing bell on Friday, March 1st 2024. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

When did Virpax Pharmaceuticals IPO?: Virpax Pharmaceuticals (VRPX) raised $15 million in an initial public offering (IPO) on Wednesday, February 17th 2021. The company issued 1,400,000 shares at a price of $10.00-$12.00 per share. ThinkEquity (a division of Fordham Financial Management) served as the underwriter for the IPO.
How do I buy shares of Virpax Pharmaceuticals?: Shares of VRPX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:VRPX) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Virpax Pharmaceuticals (VRPX) Stock Price, News & Analysis

About Virpax Pharmaceuticals Stock (NASDAQ:VRPX)

VRPX Stock Price History

VRPX Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

VRPX Stock Analysis - Frequently Asked Questions

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info